Cardiomyopathy of Duchenne muscular dystrophy: Pathogenesis and prospect of membrane sealants as a new therapeutic approach

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 1, 2007, Pages 99-109

  Townsend, DeWayne ^a   Yasuda, Soichiro ^a   Metzger, Joseph ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cardiomyopathy; Duchenne muscular dystrophy; Membrane sealant; Poloxamer 188

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DYSTROPHIN; GLUCOCORTICOID; POLOXAMER;

ARTIFICIAL HEART PACEMAKER; CALCIUM METABOLISM; CALCIUM TRANSPORT; CARDIOMYOPATHY; CHANNEL GATING; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DETERIORATION; DISEASE COURSE; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; GENE DISRUPTION; HEART ARRHYTHMIA; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYPERTROPHIC CARDIOMYOPATHY; INFECTION SENSITIVITY; MEMBRANE PERMEABILITY; MEMBRANE STABILIZATION; MUSCLE FIBER MEMBRANE; MYALGIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; UREMIA; X CHROMOSOME LINKAGE;

ANIMALS; BIOPHYSICS; CARDIOMYOPATHIES; CELL MEMBRANE; HEART; HUMANS; MUSCLE CONTRACTION; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; MYOCYTES, CARDIAC; POLOXAMER; STRESS, MECHANICAL; SURFACE-ACTIVE AGENTS;

EID: 33846474212     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.1.99     Document Type: Review

References (80)

1. Emery AEH. Clinical features. In: Duchenne Muscular Dystrophy. Emery AEH (Ed.), Oxford University Press, Oxford, UK (2003).
2. Parker AE, Robb SA, Chambers J et al. Analysis of an adult Duchenne muscular dystrophy population. QJM, 98(10), 729-736 (2005).
3. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 99(1), 1-19 (2003).
4. Kirchmann C, Kececioglu D, Korinthenberg R, Dittrich S. Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatr. Cardiol. 26(1), 66-72 (2005).
5. Ramaciotti C, Iannaccone ST, Scott WA. Myocardial cell damage in Duchenne muscular dystrophy. Pediatr. Cardiol. 24(5), 503-506 (2003).
6. Moriuchi T, Kagawa N, Mukoyama M, Hizawa K. Autopsy analyses of the muscular dystrophies. Tokushima J. Exp. Med. 40(1-2), 83-93 (1993).
7. Finsterer J, Stollberger C, Feichtinger H. Noncompaction in duchenne muscular dystrophy: Frustrated attempt to create a compensatory left ventricle? Cardiology 105(4), 223-225 (2006).
8. Markham LW, Michelfelder EC, Border WL et al. Abnormalities of diastolic function precede dilated cardiomyopathy associated with Duchenne muscular dystrophy. J. Am. Soc. Echocardiogr. 19(7), 865-871 (2006).
9. Ashford MW, Jr., Liu W, Lin SJ et al. Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging. Circulation 112(16), 2462-2467 (2005).
10. Bosser G, Lucron H, Lethor JP et al. Evidence of early impairments in both right and left ventricular inotropic reserves in children with Duchenne's muscular dystrophy. Am. J. Cardiol. 93(6), 724-727 (2004).
11. Schmidt GN, Burmeister MA, Lilje C, Wappler F, Bischoff P. Acute heart failure during spinal surgery in a boy with Duchenne muscular dystrophy. Br. J. Anaesth. 90(6), 800-804 (2003).
12. Corrado G, Lissoni A, Beretta S et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am. J. Cardiol. 89(7), 838-841 (2002).
13. McNally EM, MacLeod H. Therapy insight: Cardiovascular complications associated with muscular dystrophies. Nat. Clin. Pract. Cardiovasc. Med. 2(6), 301-308 (2005).
14. Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am. Heart J. 137(5), 895-902 (1999).
15. Duboc D, Meune C, Lerebours G et al. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 45(6), 855-857 (2005).
16. Hoffman EP, Brown RH, Jr., Kunkel LM. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51(6), 919-928 (1987).
17. Abmayr S, Chamberlain J. The Structure and Function of Dystrophin. In: Molecular Mechanims of Muscular Dystrophies. Winder SJ (Ed.) Landes Bioscience (2005)
18. Rybakova IN, Amann KJ, Ervasti JM. A new model for the interaction of dystrophin with F-actin. J. Cell. Biol. 135(3), 661-672 (1996).
19. Bhasin N, Law R, Liao G et al. Molecular extensibility of mini-dystrophins and a dystrophin rod construct. J. Mol. Biol. 352(4), 795-806 (2005).
20. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell 66(6), 1121-1131 (1991).
21. Spence HJ, Chen YJ, Winder SJ. Muscular dystrophies, the cytoskeleton and cell adhesion. Bioessays 24(6), 542-552 (2002).
22. Grady RM, Grange RW, Lau KS et al. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell Biol. 1(4), 215-220 (1999).
23. Bers DM. Cardiac excitation-contraction coupling. Nature 415(6868), 198-205 (2002).
24. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 90 (8), 3710-3714 (1993).
25. Danialou G, Comtois AS, Dudley R et al. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 15(9), 1655-1657 (2001).
26. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil. 22(5), 467-475 (2001).
27. Lynch GS, Rafael JA, Chamberlain JS, Faulkner JA. Contraction-induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice. Am. J. Physiol. Cell Physiol. 279(4), C1290-1294 (2000).
28. Hopf FW, Turner PR, Denetclaw WF, Jr., Reddy P, Steinhardt RA. A critical evaluation of resting intracellular free calcium regulation in dystrophic mdx muscle. Am. J. Physiol. 271(4 Pt 1), C1325-1339 (1996).
29. Yasuda S, Townsend D, Michele DE et al. Dystrophic heart failure blocked by membrane sealant polaxamer. Nature 436(7053), 1025-1029 (2005).
30. Alderton JM, Steinhardt RA. How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. Trends Cardiovasc. Med. 10(6), 268-272 (2000).
31. Turner PR, Fong PY, Denetclaw WF, Steinhardt RA. Increased calcium influx in dystrophic muscle. J. Cell Biol. 115(6), 1701-1712 (1991).
32. Franco A, Jr., Lansman JB. Calcium entry through stretch-inactivated ion channels in mdx myotubes. Nature 344(6267), 670-673 (1990).
33. Tidball JG, Spencer MJ. Calpains and muscular dystrophies. Int. J. Biochem. Cell Biol. 32(1), 1-5 (2000).
34. Sorimachi H, Imajoh-Ohmi S, Emori Y et al. Molecular cloning of a navel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J. Biol. Chem. 264(33), 20106-20111 (1989).
35. Salamino F, De Tullio R, Mengotti P, Melloni E, Pontremoli S. Differential regulation of mu- and m-calpain in rat hearts perfused with Ca2+ and cAMP. Biochem. Biophys. Res. Commun. 202(3), 1197-1203 (1994).
36. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol. Rev. 83(3), 731-801 (2003).
37. Sapp JL, Bobet J, Howlett SE. Contractile properties of myocardium are altered in dystrophin-deficient mdx mice. J. Neurol. Sci. 142(1-2), 17-24 (1996).
38. Janssen PM, Hiranandani N, Mays TA, Rafael-Fortney JA. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am. J. Physiol. Heart Circ. Physiol. 289(6), H2373-2378 (2005).
39. Turk R, Sterrenburg E, van der Wees CG et al. Common pathological mechanism in mouse models for muscular dystrophies. FASEB J. 20(1), 127-129 (2006).
40. Tidball JG. Inflammatory processes in muscle injury and repair. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288(2), R345-353 (2005).
41. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum. Mol. Genet. 14(14), 1921-1933 (2005).
42. Cohn RD, Durbeej M, Moore SA et al. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J. Clin. Invest. 107(2), R1-7 (2001).
43. Wheeler MT, Allikian MJ, Heydemann A et al. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J. Clin. Invest. 113(5), 668-675 (2004).
44. Thomas GD, Sander M, Lau KS et al. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl Acad. Sci. USA 95(25), 15090-15095 (1998).
45. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. (2), CD003725 (2004).
46. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: A systematic review. BMC Neurol. 3, 7 (2003).
47. Markham LW, Spicer RL, Khoury PR et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr. Cardiol. 26(6), 768-771 (2005).
48. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul. Disord. 12 Suppl 1, S169-174 (2002).
49. Lee RC, River LP, Pan FS, Ji L, Wollmann RL. Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc. Natl Acad. Sci. USA 89(10), 4524-4528 (1992).
50. Clarke MS, McNeil PL. Syringe loading introduces macromolecules into living mammalian cell cytosol. J. Cell Sci. 102 (Pt 3), 533-541 (1992).
51. Togo T, Alderton JM, Bi GQ, Steinhardt RA. The mechanism of facilitated cell membrane resealing. J. Cell Sci. 112 (Pt 5), 719-731 (1999).
52. Murhammer DW, Goochee CF. Sparged animal cell bioreactors: Mechanism of cell damage and Pluronic F-68 protection. Biotechnol. Prog. 6(5), 391-397 (1990).
53. Kabanov AV, Nazarova IR, Astafieva IV et al. Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropylene-b-oxyethylene) Macromolecules 28(27), 2303-2314 (1995).
54. Zhou Z, Chu B. Light-scattering study on the association behavior of triblock polymers of ethylene oxide and propylene oxide in aqueous solution. J. Colloid Interface Sci. 126(1), 171-180 (1988).
55. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J. Control. Release. 82(2-3), 189-212 (2002).
56. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001).
57. Yokoyama K, Suyama T, Okamoto H et al. A perfluorochemical emulsion as an oxygen carrier. Artif Organs, 8(1), 34-40 (1984).
58. Reindorf CA, Kurantsin-Mills J, Allotey JB, Castro O. Perfluorocarbon compounds: Effects on the rheological properties of sickle erythrocytes in vitro. Am J Hematol, 19(3), 229-236 (1985).
59. Smith CM, 2nd, Hebbel RP, Tukey DP et al. Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. Blood 69(6), 1631-1636 (1987).
60. Kilburn DG, Webb FC. The cultivation of animal cells at controlled dissolved oxygen partial pressure. Biotechnol. Bioeng. 10(6), 801-814 (1968).
61. Brown DA, London E. Structure and origin of ordered lipid domains in biological membranes. J. Membr. Biol. 164(2), 103-114 (1998).
62. Maskarinec SA, Hannig J, Lee RC, Lee KY. Direct observation of poloxamer 188 insertion into lipid monolayers. Biophys. J. 82(3), 1453-1459 (2002).
63. Wu G, Majewski J, Ege C et al. Interaction between lipid monolayers and poloxamer 188: An X-ray reflectivity and diffraction study. Biophys. J. 89(5), 3159-3173 (2005).
64. Ramírez OT, Mutharasan R. The role of the plasma membrane fluidity on the shear sensitivity of hybridomas grown under hydrodynamic stress. Biotechnol. Bioeng. 36(9), 911-920 (1990).
65. Clarke MS, Prendergast MA, Terry AV, Jr. Plasma membrane ordering agent pluronic F-68 (PF-68) reduces neurotransmitter uptake and release and produces learning and memory deficits in rats. Learn Mem. 6(6), 634-649 (1999).
66. Sharma V, Stebe K, Murphy JC, Tung L. Poloxamer 188 decreases susceptibility of artificial lipid membranes to electroporation. Biophys. J. 71(6), 3229-3241 (1996).
67. Grindel JM, Jaworski T, Piraner O, Emanuele RM, Balasubramanian M. Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J. Pharm. Sci. 91(9), 1936-1947 (2002).
68. Jewell RC, Khor SP, Kisor DF, LaCroix KA, Wargin WA. Pharmacokinetics of RheothRx injection in healthy male volunteers. J. Pharm. Sci. 86(7), 808-812 (1997).
69. Lane TA, Lamkin GE. Paralysis of phagocyte migration due to an artificial blood substitute. Blood 64(2), 400-405 (1984).
70. Lane TA, Lamkin GE. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood 68(2), 351-354 (1986).
71. Maynard C, Swenson R, Paris JA et al. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. Am. Heart J. 135(5 Pt 1), 797-804 (1998).
72. Gibbs WJ, Hagemann TM. Purified poloxamer 188 for sickle cell vaso-occlusive crisis. Ann. Pharmacother. 38(2), 320-324 (2004).
73. Grindel JM, Jaworski T, Emanuele RM, Culbreth P. Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharm. Drug Dispos. 23(3), 87-103 (2002).
74. Ballas SK, Files B, Luchtman-Jones L et al. Safety of purified poloxamer 188 in sickle cell disease: Phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 28(2), 85-102 (2004).
75. Moghimi SM, Hunter AC, Dadswell CM et al. Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim. Biophys. Acta 1689(2), 103-113 (2004).
76. Orringer EP, Casella JF, Ataga KI et al. Purified polaxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA 286(17), 2099-2106 (2001).
77. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 116(6), 1569-1573 (2005).
78. Barst RJ, Rubin LJ, McGoon MD et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. 121(6), 409-415 (1994).
79. Badorff C, Lee GH, Lamphear BJ et al. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5(3), 320-326 (1999).
80. Vatta M, Stetson SJ, Jimenez S et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J. Am. Coll. Cardiol. 43(5), 811-817 (2004).